Renewed talk of a Gilead – Bristol Myers Squibb deal

The magazine Barrons published a report by a pharmaceutical analyst who considers Gilead likely to acquire Bristol-Myers Squibb. Such a large acquisition could upturn Gilead’s negative trend – the company has already delivered several negative quarter results. BMS has a market value of $97bn, Gilead has one of $79bn, that is almost half of last year’s value. The analyst mentioned Biomarin and Incyte as other potential targets for Gilead.
(Source Barrons)